Your browser is no longer supported. Please, upgrade your browser.
Settings
BLCM Bellicum Pharmaceuticals, Inc. daily Stock Chart
BLCM [NASD]
Bellicum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.99 Insider Own0.60% Shs Outstand32.71M Perf Week14.78%
Market Cap215.89M Forward P/E- EPS next Y-2.93 Insider Trans-82.07% Shs Float29.22M Perf Month-17.40%
Income-89.80M PEG- EPS next Q-0.70 Inst Own56.50% Short Float15.79% Perf Quarter-30.53%
Sales0.30M P/S719.62 EPS this Y-39.40% Inst Trans-0.05% Short Ratio6.60 Perf Half Y-13.39%
Book/sh3.11 P/B2.12 EPS next Y0.30% ROA-56.50% Target Price15.00 Perf Year-51.15%
Cash/sh3.46 P/C1.91 EPS next 5Y- ROE-77.20% 52W Range5.02 - 15.55 Perf YTD-21.52%
Dividend- P/FCF- EPS past 5Y- ROI-58.40% 52W High-57.56% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low31.47% ATR0.56
Employees110 Current Ratio6.10 Sales Q/Q0.00% Oper. Margin- RSI (14)47.01 Volatility6.00% 8.01%
OptionableYes Debt/Eq0.30 EPS Q/Q-7.50% Profit Margin- Rel Volume1.74 Prev Close5.97
ShortableYes LT Debt/Eq0.23 EarningsMar 12 AMC Payout- Avg Volume699.20K Price6.60
Recom1.60 SMA20-2.96% SMA50-17.75% SMA200-34.93% Volume1,216,220 Change10.55%
Jan-31-18Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17Initiated Wells Fargo Outperform
Dec-01-16Initiated Raymond James Outperform
Nov-30-16Initiated Ladenburg Thalmann Buy
Nov-02-16Initiated Cantor Fitzgerald Buy $32
Aug-09-16Upgrade Citigroup Neutral → Buy
Feb-25-16Initiated Citigroup Neutral $11
Sep-11-15Upgrade Guggenheim Neutral → Buy
Jul-24-15Initiated Citigroup Buy
Feb-17-18 11:20AM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
08:00AM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM PR Newswire
Feb-15-18 04:12PM  BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action BLCM Business Wire
Feb-14-18 07:15PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM ACCESSWIRE
Feb-13-18 06:24PM  BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
10:46AM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCM ACCESSWIRE
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline April 9, 2018 GlobeNewswire
Feb-12-18 03:17PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. GlobeNewswire
Feb-10-18 09:07AM  Is Bellicum Pharmaceuticals, Inc. a Buy Now? Motley Fool
Feb-09-18 04:50PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM ACCESSWIRE
12:36PM  Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class Action Business Wire
08:30AM  Todays Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian Therapeutics ACCESSWIRE
Feb-08-18 03:35PM  Ongoing Investigation: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE -10.58%
02:45PM  Here's how Triad stocks fared this week American City Business Journals
01:31PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
Feb-07-18 07:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bellicum Pharmaceuticals, Inc. (BLCM) GlobeNewswire +10.66%
12:20PM  The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018 PR Newswire
Feb-06-18 10:18PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
03:33PM  Here are the U.S. stocks getting pummeled in the market rout American City Business Journals
03:21PM  Here are the D.C.-area stocks getting pummeled in the market rout American City Business Journals
03:13PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. BLCM Business Wire
02:52PM  BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm PR Newswire
01:53PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers BLCM GlobeNewswire
01:25PM  Here are the Houston stocks that were walloped during the market's drop (update) American City Business Journals
Feb-05-18 07:00AM  Bellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical Officer GlobeNewswire
Jan-31-18 01:26PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellicum Pharmaceuticals, Inc. (BLCM) PR Newswire -25.85%
12:41PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bellicum Pharmaceuticals, Inc. - BLCM PR Newswire
11:57AM  Why Bellicum Pharmaceuticals Stock Is Crashing Today Motley Fool
09:14AM  Heres Whats Moving Bellicum Pharmaceuticals And Achaogen Market Exclusive
08:20AM  Todays Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Corcept Therapeutics ACCESSWIRE
Jan-30-18 04:47PM  Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States GlobeNewswire -5.53%
Jan-25-18 10:27AM  Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet? Motley Fool
Jan-05-18 03:00PM  Bellicum Pharmaceuticals Is Failing to Capture Investors' Imagination Motley Fool
Dec-29-17 11:36AM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : December 29, 2017 Capital Cube
Dec-28-17 08:38AM  Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017 Capital Cube
Dec-18-17 02:51PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : December 18, 2017 Capital Cube
Dec-11-17 10:00AM  Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting GlobeNewswire
Dec-09-17 02:00PM  Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases GlobeNewswire
Nov-08-17 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire +6.56%
Nov-07-17 04:05PM  Bellicum Reports Third Quarter 2017 Financial Results GlobeNewswire
11:03AM  Is It Time To Buy Bellicum Pharmaceuticals Inc (BLCM)? Simply Wall St.
Nov-01-17 09:17AM  Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-24-17 08:13AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : October 24, 2017 Capital Cube
Sep-27-17 06:54AM  Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish InvestorPlace
Sep-11-17 10:38AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : September 11, 2017 Capital Cube
Sep-05-17 10:52PM  Bellicum Pharmaceuticals, Inc. Value Analysis (NASDAQ:BLCM) : September 6, 2017 Capital Cube
Sep-01-17 09:49AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : September 1, 2017 Capital Cube
Aug-30-17 07:00AM  Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September GlobeNewswire
Aug-29-17 08:43AM  Bellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher Zacks +7.22%
Aug-13-17 07:46AM  Edited Transcript of BLCM earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:35AM  Houston pharma co. shakes up C-suite again American City Business Journals -9.31%
Aug-08-17 04:05PM  Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
01:10PM  Investor Network: Bellicum Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 07:00AM  Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer GlobeNewswire
Aug-01-17 07:00AM  Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017 GlobeNewswire
Jul-28-17 09:31AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : July 28, 2017 Capital Cube
Jul-24-17 02:24PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
Jul-18-17 08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
Jul-16-17 08:03PM  3 Value Stocks for Sharp Investors Motley Fool
Jul-14-17 02:41PM  Can Bellicum Pharmaceuticals Stock Bounce Back? Motley Fool
01:06PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 14, 2017 Capital Cube
08:30AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : July 14, 2017 Capital Cube
Jul-03-17 04:11PM  Bellicum Pharmaceuticals, Inc. Value Analysis (NASDAQ:BLCM) : July 3, 2017 Capital Cube
Jun-30-17 09:26AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : June 30, 2017 Capital Cube
Jun-29-17 04:05PM  Here's Why Bellicum Pharmaceuticals Fell as Much as 13.8% Today Motley Fool -9.72%
Jun-28-17 09:29AM  Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers TheStreet.com
Jun-27-17 03:07PM  Analysts Remain Encouraged By Bellicum Pharma's Progress Benzinga
02:59PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : June 27, 2017 Capital Cube
Jun-26-17 11:11AM  Bellicum Pharmaceuticals EHA Presentation Helps Validate Its Platform Benzinga
Jun-23-17 12:14PM  Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout TheStreet.com
07:00AM  Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association GlobeNewswire
07:00AM  Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association GlobeNewswire
Jun-22-17 09:36AM  Biotech Movers: Shire, Bellicum, Organovo TheStreet.com +10.51%
Jun-20-17 08:23AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : June 20, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Rigel Pharmaceuticals and Bellicum Pharmaceuticals Accesswire
Jun-16-17 03:28PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : June 16, 2017 Capital Cube +8.11%
Jun-05-17 02:03PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:38AM  Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-31-17 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire -6.61%
May-18-17 07:00AM  Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association GlobeNewswire
May-17-17 04:23PM  3 Growth Stocks You Haven't Thought Of Motley Fool -5.14%
May-16-17 08:45AM  Houston pharmaceutical company announces C-level changes American City Business Journals
May-15-17 04:30PM  Bellicum Pharmaceuticals Announces Management Changes GlobeNewswire
May-11-17 06:17PM  Bellicum Pharmaceuticals, Inc. Value Analysis (NASDAQ:BLCM) : May 11, 2017 Capital Cube
May-09-17 08:52AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : May 9, 2017 Capital Cube
May-08-17 04:05PM  Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire -6.60%
Apr-26-17 07:00AM  Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-21-17 09:34AM  Biotech Movers: XBiotech, Atara, Bellicum TheStreet.com
Apr-11-17 08:15AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : April 11, 2017 Capital Cube
Apr-06-17 04:20PM  The First CAR-T Drugs Have Left the Gate Motley Fool
Apr-05-17 09:23AM  Biotech Movers: Sarepta, Bellicum, Novavax TheStreet.com
Apr-04-17 08:00AM  Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR GlobeNewswire
Mar-30-17 07:00AM  Bellicum Pharmaceuticals Announces Closing of Public Offering GlobeNewswire
Mar-29-17 08:42AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma Motley Fool +5.03%
Mar-27-17 03:51PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
Mar-24-17 04:23PM  BELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -6.67%
08:14AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : March 24, 2017 Capital Cube
Mar-23-17 06:20PM  Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -10.23%
Mar-22-17 04:01PM  Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. It has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant (HSCT); BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. The company has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LP10% OwnerJan 19Sale7.91295,3612,336,21758,131Jan 19 04:57 PM
BAKER BROS. ADVISORS LP10% OwnerJan 18Sale8.12324,7742,635,76862,267Jan 19 04:57 PM
BAKER BROS. ADVISORS LP10% OwnerJan 17Sale8.63260,6002,247,91066,815Jan 19 04:57 PM
Smith Alan K.EVP, Technical OperationsJan 09Sale9.404874,5782,087Jan 11 04:02 PM
Musso Alan ACFO and TreasurerDec 11Sale9.3317,117159,66731,585Dec 13 04:05 PM
Smith Alan K.EVP, Technical OperationsJul 24Sale11.854375,1781,600Jul 26 04:29 PM
Moseley KenSr. VP and General CounselJul 13Option Exercise2.5513,82335,24914,314Jul 17 04:20 PM
Moseley KenSr. VP and General CounselJul 13Sale12.2613,823169,470491Jul 17 04:20 PM
Spencer David M.Chief Scientific OfficerJul 10Sale11.5410,000115,400138,965Jul 12 04:43 PM
Musso Alan ACFO and TreasurerMay 25Sale12.246,31177,25454,908May 26 03:07 PM
BAKER BROS. ADVISORS LP10% OwnerMar 24Buy12.00166,6661,999,9924,527,089Mar 28 05:05 PM